NCT00165399已完成2 期
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Definitive Local Treatment
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 10
- 主要终点
- To determine the feasibility of administering chemotherapy and medical castration to men with rising PSA after radical prostatectomy or radiation therapy.
研究概览
简要总结
The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer.
This study will attempt to:
- stop or slow the growth of disease
- gain information about prostate cancer
- evaluate the effectiveness and side effects of the study drug
详细描述
- Patients will receive two medications; docetaxel and estramustine. Estramustine will be taken orally three times daily for 5 days starting on day one. Docetaxel will be given intravenously on day 2. These two drugs will be repeated every 3 weeks for a total of 4 cycles (12 weeks).
- Patients will also take dexamethasone for three days at the beginning of each cycle to help decrease the risk of side effects.
- Patients will also take coumadin every day for three months while on the chemotherapy to reduce the risk of blood clots.
- After 12 weeks the chemotherapy phase will be completed and patient will start on the hormone therapy part of the treatment. Three weeks after the last chemotherapy treatment, patients will start Casodex orally once daily.
- After taking Casodex for 1 week, patients will then start on Zoladex (an injection in the abdomen) every 3 months for a total of 5 injections.
- During study treatment various blood tests will be performed to watch the disease. Study treatment will stop after a total of 18 months (3 months chemotherapy and 15 months hormone therapy). A physical exam and blood tests will be performed every 3 months for 2 years, every 4 months for the third year, and then every 6 months after that.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically documented adenocarcinoma of the prostate
- •Previous treatment with either radical prostatectomy or radiation therapy
- •Post prostatectomy: PSA rising on at least two successive occasions at least two weeks apart
- •Post radiation therapy alone: PSA has to be rising as documented on two successive occasions at least two weeks apart and also have doubled from the nadir post treatment value
- •ECOG performance status 0-1
- •ANC > 1,500/mm3
- •Platelet counts > 100,000/mm3
- •SGOT and/or SGPT may be up to 2.5 x ULN
排除标准
- •Documented local recurrence of prostate cancer or documented metastatic disease
- •History of other malignancy within the last 5 years, other than curatively treated basal cell carcinoma of the skin
- •Medical condition requiring the use of concommitant corticosteroids
- •Active infection
- •Significant cardiac disease, angina pectoris or myocardial infarction within six months
- •Prior chemotherapy including estramustine, suramin
- •Active thrombophlebitis or history of thromboembolic events in the six months preceding study treatment
- •Clinically significant neuropathy
- •Elevated bilirubin above ULN
结局指标
主要结局
To determine the feasibility of administering chemotherapy and medical castration to men with rising PSA after radical prostatectomy or radiation therapy.
时间窗: 2 years
次要结局
- To determine the PSA response rate and duration of response
- to measure testosterone, free testosterone, and sex hormone binding globulin in relation to chemotherapy and hormone therapy.(2 years)
研究者
Mary-Ellen Taplin, MD
Associate Professor of Medicine, HMS
Dana-Farber Cancer Institute
研究点 (10)
Loading locations...
相似试验
已完成
3 期
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate CancerProstate CancerNCT00116142Dana-Farber Cancer Institute350
已完成
2 期
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate CancerProstate CancerNCT01250717Beth Israel Deaconess Medical Center28
已完成
2 期
Docetaxel With a Phytochemical in Treating Patients With Hormone Independent Metastatic Prostate CancerMetastatic Prostate CancerNCT01012141Centre Jean Perrin30
终止
2 期
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSAProstate CancerNCT01531205H. Lee Moffitt Cancer Center and Research Institute2
已完成
2 期
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerLung CancerNCT00114192University of Virginia37